Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company's thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Bernard And Vima’s Mission
- 2:40Lessons From NIH And Research Gaps
- 5:20Rochester Bridge To Industry
- 9:40Why Move To Biotech And CMO Roles
- 14:10Growing Into The CEO Seat
- 18:20Choosing Atlas And Founding Vima
- 22:10Raising A $60M Series A
- 25:30Stealth Mode: Why And When To Launch
- 28:20Inside VIM-0423 And Its Rationale
- 32:00Muscarinic Receptors: Antagonists Versus Agonists
- 35:30Dystonia Unmet Need And Patients
- 39:00Indication Strategy And Expansion Paths
- 41:20Clinical Plan, Timelines, And Trial Design